| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT05412394 Once Weekly Infant Corticosteroid Trial for DMD · Anne M. Connolly |
date change Primary completion pushed: 2026-08 -> 2028-08 |
| 2026-08-15 | NCT05412394 Once Weekly Infant Corticosteroid Trial for DMD · Anne M. Connolly |
date change Completion pushed: 2026-12 -> 2028-12 |
| 2026-08-15 | NCT07287189 Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Satellos Bioscience, Inc. |
date change Completion pushed: 2027-06-30 -> 2028-02-28 |
| 2026-08-13 | NCT07347548 A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male… · Grünenthal GmbH |
Trial completed |
| 2026-08-12 | NCT05524883 Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in… · Dyne Therapeutics |
date change Primary completion pushed: 2029-11 -> 2031-09 |
| 2026-08-12 | NCT05524883 Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in… · Dyne Therapeutics |
date change Completion pushed: 2029-11 -> 2031-09 |
| 2026-08-12 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… · Avidity Biosciences, Inc. |
Trial sites expanded: 7 -> 10 locations |
| 2026-08-05 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… · Avidity Biosciences, Inc. |
Recruitment opened |
| 2026-08-05 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… · Avidity Biosciences, Inc. |
Trial sites expanded: 0 -> 7 locations |
| 2026-08-04 | NCT06594094 An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR… · HuidaGene Therapeutics Co., Ltd. |
Sponsor refiled this as active, not recruiting (was completed) |
| 2026-07-31 | NCT06244082 Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With… · Avidity Biosciences, Inc. |
date change Completion moved earlier: 2027-07-31 -> 2027-04-30 |
| 2026-07-25 | NCT04972604 CureDuchenne Link®: A Resource for Research · CureDuchenne |
Trial completed |
| 2026-07-25 | NCT04972604 CureDuchenne Link®: A Resource for Research · CureDuchenne |
Enrollment reduced: 5000 -> 240 participants |
| 2026-07-25 | NCT04972604 CureDuchenne Link®: A Resource for Research · CureDuchenne |
date change Primary completion moved earlier: 2031-07-09 -> 2025-12-12 |
| 2026-07-25 | NCT04972604 CureDuchenne Link®: A Resource for Research · CureDuchenne |
date change Completion moved earlier: 2031-07-09 -> 2025-12-12 |
| 2026-07-22 | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… · REGENXBIO Inc. |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-22 | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… · REGENXBIO Inc. |
Trial sites expanded: 17 -> 23 locations |
| 2026-07-22 | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… · REGENXBIO Inc. |
date change Primary completion pushed: 2026-08 -> 2026-09 |
| 2026-07-22 | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… · REGENXBIO Inc. |
date change Completion moved earlier: 2028-08 -> 2028-06 |
| 2026-07-22 | NCT07172971 Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Vanderbilt University Medical Center |
Sponsor changed: Larry W. Markham -> Vanderbilt University Medical Center |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-07-15 | NCT07704099 Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy | Keros Therapeutics, Inc. NEW | Phase 2 |
| 2026-06-29 | NCT07673809 A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in… | AO GENERIUM NEW | Phase 1/2 |
| 2026-06-23 | NCT07664124 Digital Monitoring of Upper Limb Function in Non-Ambulant DMD | Centre Hospitalier Universitaire de Liege NEW | |
| 2026-06-05 | NCT07629284 Home-Based Tele-Rehabilitation for Respiratory Function in Children With Duchenne… | Samsung Medical Center NEW | |
| 2026-05-27 | NCT07608432 Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered… | Dyne Therapeutics NEW | Phase 3 |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05412394 | Once Weekly Infant Corticosteroid Trial for DMD | Anne M. Connolly | Recruiting |
| NCT04687020 | Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical… | NS Pharma, Inc. | Active, Not Recruiting |
| NCT06713135 | A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With… | Santhera Pharmaceuticals | Active, Not Recruiting |
| NCT07542314 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne… | Sarepta Therapeutics, Inc. | Not Yet Recruiting |
| Phase 3 | |||
| NCT07608432 | Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered… | Dyne Therapeutics | Recruiting |
| NCT05933057 | Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne… | Italfarmaco | Recruiting |
| NCT07587242 | A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… | Avidity Biosciences, Inc. | Recruiting |
| NCT07160634 | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy… | Solid Biosciences Inc. | Recruiting |
| NCT04587908 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | Taiho Pharmaceutical Co., Ltd. | Active, Not Recruiting |
| NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec… | Sarepta Therapeutics, Inc. | Enrolling by Invitation |
| NCT03992430 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With… | Sarepta Therapeutics, Inc. | Active, Not Recruiting |
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene… | Sarepta Therapeutics, Inc. | Active, Not Recruiting |
| NCT05126758 | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne… | Capricor Inc. | Active, Not Recruiting |
| NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne… | Pfizer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03373968 | Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study | Italfarmaco | Recruiting |
| NCT05195775 | Tadalafil as Adjuvant Therapy for DMD | University of Florida | Active, Not Recruiting |
| NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… | REGENXBIO Inc. | Active, Not Recruiting |
| Phase 2 | |||
| NCT06769633 | Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to… | Italfarmaco | Recruiting |
| NCT05996003 | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | Recruiting |
| NCT06290713 | Vasodilator and Exercise Study for DMD (VASO-REx) | University of Florida | Recruiting |
| NCT07287189 | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | Satellos Bioscience, Inc. | Recruiting |
| NCT05135663 | Extension Study of NS-089/NCNP-02 in DMD | Nippon Shinyaku Co., Ltd. | Active, Not Recruiting |
| NCT06643442 | Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age | Sebastiano Lava | Not Yet Recruiting |
| NCT04433234 | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Daiichi Sankyo Co., Ltd. | Active, Not Recruiting |
| NCT04428476 | Open-label Extension of the HOPE-2 Trial | Capricor Inc. | Active, Not Recruiting |